Evommune to receive up to $60 million in upfront and milestone payments, and is eligible for tiered royalty payments on future sales of EVO756 in Japan Company provides pipeline update: Based on Phase 2a results of EVO101 in atopic dermatitis, Evommune will no longer pursue this program…